Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Role of Bumetanide in Treatment of Autism

Role of bumetanide in Autism

  • 15 views
  • 02 Mar, 2021
  • 1 location
Mechanisms of Diuretic Resistance in Heart Failure (MDR)

This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 50 diuretic resistant HF patients and 25 diuretic responsive heart failure (HF) patients.

heart failure
bumetanide
  • 0 views
  • 20 Jul, 2022
  • 1 location
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (DECONGEST)

This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic administration and with low-threshold use of combination diuretic therapy, improves decongestion versus usual care in acute heart failure (AHF), potentially …

  • 0 views
  • 03 Jul, 2022
  • 1 location
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion

Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics. Up to 24 subjects will be enrolled in up to 3 centres in Republic of Georgia, and randomized into 2 parallel treatment arms. Once implanted with …

fluid overload
nt-probnp
torsemide
loop diuretic
congestion
  • 0 views
  • 09 Jun, 2021
  • 2 locations
Lokelma for RAAS Maximisation in CKD & Heart Failure. (LIFT)

Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of hyperkalaemia. New potassium binders, e.g. Sodium Zirconium Cyclosilicate (SZC), reduce incidence of hyperkalaemia in CKD-HF patients and hence may …

aldosterone
heart failure
  • 0 views
  • 14 Mar, 2022